Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
The field is reaching a point where sleep health will become a top priority for public health as a result of the great strides made in the field over the past year, as well as the effects of the COVID-19 pandemic and lingering care challenges.
Read Full News(This Aug 27 story has been republished, with no changes to text.)
Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.
After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.
Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.
Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.
1.
Chemotherapy Boosts Survival for Older Patients With TNBC
2.
Study reveals link between new-onset type 2 diabetes and some obesity-related cancers
3.
EMA Backs Breast Cancer SERD After FDA No Vote
4.
Discovery of estrogen receptor 'switches' may aid breast cancer treatment
5.
Insurance Claim Denials for Preventive Care More Common in At-Risk Patients
1.
Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology
2.
Immune Recovery After Intensive Cancer Therapy
3.
Community Survivorship Networks for Long-Term Cancer Wellness
4.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
5.
Clonal Hematopoiesis and Healthy Aging: Insights, Mechanisms, and Clinical Relevance
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Navigating the Complexities of Ph Negative ALL - Part XIV
4.
From Guidelines to Practice: Hematology
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge